BioSpace News Archive

Simon Greenstone Panatier trial lawyer: Jury’s large punitive award sends message [07-February-2020] NEW BRUNSWICK, N.J. , Feb. 7, 2020 /PRNewswire/ -- A New Jersey jury has ordered Johnson & Johnson (NYSE:JNJ) to pay $750 million in punitive damages to four cancer victims who charged that the company’s iconic Johnson’s Baby Powder contained cancer-causing a

Registration is open for the Global Cannabis Research Summit on April 22, 2020 at the New Jersey Hospital Association Conference Center in Princeton, NJ.

PHILADELPHIA, Pa. and OXFORD, United Kingdom, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that the underwriters of its previously announced public offering of 21,000,000 American Depositary Shares (“ADSs”), which initially closed on January 24, 2020, have exercised in full their option to purchase an additional 3,150,000 of its ADSs at a price to the public of $4.00 per ADS, raising a

Company will Release Results on Monday, February 10th at 7:00am Followed by an Investor Call Starting at 8:30am ET

Alireza Moshaverinia, DDS, MS, PhD, FACP, was honored with the Distinguished Researcher Award from the American College of Prosthodontists.

Feb. 7, 2020 21:30 UTC The addition of three lab locations complements Zoetis’ growing reference laboratory footprint and enhances its value to veterinarians in the U.S. PARSIPPANY, N.J. & WOBURN, Mass.--( BUSINESS WIRE )-- Zoetis Inc . (NYSE:ZTS) today announced the acquisition of Ethos Diagnostic Science, a veterinary reference lab business dedicated to serving leading specialty animal hospitals, the greater veterinary community and researchers with accurate, reliabl

Kaiser Foundation Health Plan, Inc., Kaiser Foundation Hospitals and their respective subsidiaries (KFHP/H) reported 2019 annual financial results. Total operating revenues for 2019 were $84.5 billion , compared to $79.7 billion in 2018. Operating expenses were $81.8 billion , compared to $77.8 billion in the prior year. Ope

Feb. 7, 2020 23:20 UTC Data presented at the 9 th Annual Glaucoma 360 New Horizons Forum CINCINNATI--( BUSINESS WIRE )-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, announced that Kevin Peters, M.D., Aerpio’s Chief Scientific Officer, presented data from the fifth cohort of subjects from a Phase 1b trial showing the potential of a topical ocu

The Phantom® ActivCore Nail addresses TTC arthrodesis and is the second of three hindfoot fusion nailing systems Paragon 28® plans to launch in 2020.

Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a global commercial manufacturer of high quality cannabinoid-based ingredients, formulations and products, announces the following changes to its Board of Directors, effective today.